Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Jan 21, 2027; 33(3): 127331
Published online Jan 21, 2027. doi: 10.3748/wjg.127331
Published online Jan 21, 2027. doi: 10.3748/wjg.127331
Randomized trial of vonoprazan dual therapy vs bismuth-containing quadruple therapy with two low-resistance antibiotics for Helicobacter pylori eradication
Jian-Hong Chen, Xiao-Wen Liu, Yan-Ting Xu, Ning Wang, Jun-Feng Guo, Lu-Yang Chen, Fu-Sheng Gao, Chuan Zhang, Department of Gastroenterology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
Co-corresponding authors: Fu-Sheng Gao and Chuan Zhang.
Author contributions: Chen JH, Zhang C, and Gao FS designed this study; Chen JH, Liu XW, Xu YT, Wang N, Guo JF and Chen LY screened patients and acquired clinical data. Chen JH, Gao FS, and Zhang C performed data analysis and interpretation; Chen JH drafted the manuscript. All the authors have read and approved the final manuscript. Zhang C and Gao FS have played important roles in the study design and data analysis as the co-corresponding authors. Zhang C and Gao FS conceived, designed, and supervised the study, and performed data analysis and interpretation.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement. The authors carefully reviewed and verified all AI-assisted outputs and take full responsibility for the scientific content of the manuscript.
Supported by the National Natural Science Foundation of China, No. 81900505; and Beijing Municipal Administration of Hospitals’ Youth Program, No. QML20200702.
Institutional review board statement: The study protocol received ethical approval from the independent Ethics Committee of Beijing Tongren Hospital (Approval No. TREC2025-KY070).
Clinical trial registration statement: This study is registered at https://www.chictr.org.cn/showprojEN.html?proj=278033. The registration identification number is ChiCTR2500105014.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: De-identified participant-level data, statistical code, and the data dictionary used in this study are available from the corresponding author upon reasonable request, subject to institutional and ethical approvals.
Corresponding author: Chuan Zhang, MD, Department of Gastroenterology, Beijing Tongren Hospital, Capital Medical University, No. 1 Dongjiaomin Lane, Dongcheng District, Beijing 100730, China. digestivezhang@163.com
Received: August 28, 2026
Revised: September 20, 2026
Accepted: November 4, 2026
Published online: January 21, 2027
Processing time: 78 Days and 15 Hours
Revised: September 20, 2026
Accepted: November 4, 2026
Published online: January 21, 2027
Processing time: 78 Days and 15 Hours
Core Tip
Core Tip: This single-center, open-label randomized trial compared vonoprazan-amoxicillin (VA) dual therapy with vonoprazan-based bismuth-containing quadruple therapy containing amoxicillin and minocycline (VBAM) in treatment-naïve Helicobacter pylori infection. VA was non-inferior to VBAM in eradication rates across all analysis sets. Overall adverse events were comparable, but VA had fewer dizziness events. From a healthcare payer perspective, VA had lower direct medical costs. However, the generalizability of these findings to broader populations and different resistance patterns requires further investigation.